title: Antiarrhythmic use from 1991 to 2007: insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II).
abstract: BACKGROUND
  The pharmacologic management of atrial fibrillation (AF), the most common sustained cardiac arrhythmia, has been traditionally dichotomized into control of ventricular rate or re-establishment and maintenance of sinus rhythm.
  
  
  OBJECTIVE
  The purpose of this study was to evaluate the use of rate-controlling drugs and antiarrhythmic drugs (AAD) in the Canadian Registry of Atrial Fibrillation (CARAF) over a 16-year period from 1991 through 2007.
  
  
  METHODS
  1,400 patients with new-onset paroxysmal AF who were enrolled in CARAF were included in this analysis. We assessed trends in ventricular rate-controlling medication use (digoxin, beta-blockers, and calcium channel blockers) and AAD (class IA, IC, and III antiarrhythmic agents) at baseline and follow-up visits as well as by calendar year.
  
  
  RESULTS
  AAD use increased initially from 1991 to 1994 (peak use 42.5%) before steadily declining. Sotalol use decreased (27% to 6%), whereas amiodarone use increased (1.6% to 17.9%). Rate-controlling medication use decreased from 1991 to 1995 (54.1% to 34.1%) due to declining digoxin use (62.9% to 16.3%). After 1999, there was a continued increase in rate-controlling medication use (peak use 52.5% in 2007) due to increased beta-blocker use (17% to 45.7%). Calcium channel blockers use changed little over the duration of the study.
  
  
  CONCLUSIONS
  The management of AF has undergone significant shifts since 1990, reflecting the influence of drug development, prevailing belief systems, the impact of large clinical trials, and evidence-based recommendations. Monitoring of pharmacotherapy trends will provide insight into the real-world application of evidence-based guidelines as well as allow the opportunity to identify deficiencies and improve patient care.
authors.affiliation: St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Jason G
authors.initials: JG
authors.lastname: Andrade
authors.forename: Stuart J
authors.initials: SJ
authors.lastname: Connolly
authors.forename: Paul
authors.initials: P
authors.lastname: Dorian
authors.forename: Martin
authors.initials: M
authors.lastname: Green
authors.forename: Karin H
authors.initials: KH
authors.lastname: Humphries
authors.forename: George J
authors.initials: GJ
authors.lastname: Klein
authors.forename: Robert
authors.initials: R
authors.lastname: Sheldon
authors.forename: Mario
authors.initials: M
authors.lastname: Talajic
authors.forename: Charles R
authors.initials: CR
authors.lastname: Kerr
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002170:Canada / Q000453:epidemiology; D004562:Electrocardiography / Q000187:drug effects; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D009017:Morbidity / Q000639:trends; D011446:Prospective Studies; D012042:Registries; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers